Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZJ-S-0106
- Development stage
- Unknown
- Lead developer
- Shenzhen Second People’s Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ZJ-S-0106 is an investigational cell therapy consisting of CD73-positive natural killer (NK) cells, currently under development by Shenzhen Second People's Hospital for the treatment of mild to moderate Alzheimer's disease. The product utilizes NK cells—innate immune cells known for their role in surveillance and regulation—that have been characterized by the expression of CD73 (5'-nucleotidase). CD73 plays a critical role in the purinergic signaling pathway by catalyzing the conversion of adenosine monophosphate (AMP) to adenosine, a nucleoside with potent anti-inflammatory and neuroprotective properties. By introducing these cells, the therapy aims to modulate the neuroinflammatory environment in the brain, potentially reducing the progression of Alzheimer's disease. A multicenter clinical trial (ChiCTR2600125767) is evaluating the safety, pharmacokinetics, and preliminary efficacy of ZJ-S-0106 in patients also receiving rehabilitation therapies.
- Other names
- CD73+NK cells
02
Targets
NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on ZJ-S-0106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZJ-S-0106.